Gram-negative R&D pipelines dry up

Gram-negative R&D pipelines dry up

GSK has pressed the “pause” button and halted collaboration on one of the few promising novel anti-Gram-negative compounds that had progressed beyond Phase 1. Here is yet another warning sign that antibacterial pipelines are under close scrutiny and may dry up quickly and completely.

My recent review article “Accelerating resistance, inadequate antibacterial drug pipelines and international responses” in the International Journal of Antimicrobial Agents details the critical health problem of growing multidrug resistance in the face of slim prospects for novel treatments. However there is hope, as the threat of untreatable infectious diseases has spurred national and international government responses. Read more in my new publication.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s